23rd June 2021

NHS Wales Contract Award For Yourgene Health

Molecular diagnostics group Yourgene Health has been awarded a contract to supply its Elucigene DPYD testing kits to NHS Wales.

The contract award is for up to two years and is estimated to be worth £232,000.

The Elucigene DPYD1 screens cancer patients prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil, to identify the risk of severe side effects. Wales was the first nation in the UK to routinely implement this screening and offer the DPYD test to all patients, with Yourgene being the sole provider, as announced in October 2020.

Due to the considerable increase in the demand for the test the All Wales Genomics Laboratory (AWMGL) has awarded Yourgene this contract, due to commence in July 2021.

Lyn Rees, chief executive of Yourgene Health, said: “We are extremely pleased to be awarded this tender to supply our IVD-marked oncology product to NHS Wales, with our differentiated technology deemed the only technology suitable for meeting the lab requirements to deliver the service.

“We are proud to see this form of personalised medicine increasing in demand and routinely being used across Wales.”